Search
HNM01
go.drugbank.com/drugs/DB06531ExperimentalThe drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor. … It entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase
Abetimus
go.drugbank.com/drugs/DB06662InvestigationalAbetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.
IDM-2
go.drugbank.com/drugs/DB05293ExperimentalIDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells.
LAX-101
go.drugbank.com/drugs/DB05301InvestigationalThe molecules of EPA found in LAX-101 are identical to the molecules of EPA found in fish oil food supplements. … The active molecule in LAX-101 is Eicosapentaenoic Acid (EPA). All molecules of EPA are identical.
NE-180
go.drugbank.com/drugs/DB05619ExperimentalNE-180 was under investigation in a clinical trial conducted in the European Union.
Acrivastine
go.drugbank.com/drugs/DB09488ApprovedAcrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D. … Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever.
Synonyms: (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}acrylic acidTrandolaprilat
go.drugbank.com/drugs/DB14209ExperimentalThe active metabolite of the prodrug Trandolapril.
Categories: Agents Acting on the Renin-Angiotensin SystemHLX70
go.drugbank.com/drugs/DB16509Investigationalin healthy adult volunteers. … The condition targeted by HLX70 in this study is COVID-19.
SVV-001
go.drugbank.com/drugs/DB06129InvestigationalSVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. … SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that of traditional chemotherapeutics with no overt toxicity at doses one million times higher than effective doses in
AVE9633
go.drugbank.com/drugs/DB06318InvestigationalAVE9633 is an anti-CD33 monoclonal antibody-DM4 conjugate.